Accessibility Menu
Emyria logo

Emyria(ASX) EMD

Market CapA$37.10MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-68%
5 Year-76%
1 Year+10%
1 Month+18%
A$0.05
+0.00%
+0.00Today
Emyria last closing stock price
MetricPriceDate
Last closeAUD 0.052026-08-13
Emyria stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-6.12%AUD 0.052026-08-06
1 month+17.95%AUD 0.042026-07-14
3 month+17.95%AUD 0.042026-05-15
Year to date-22.03%AUD 0.062025-12-31
1 year+9.52%AUD 0.042025-08-13
3 year-52.08%AUD 0.102023-08-14
5 year-76.41%AUD 0.202021-08-13
Since inception-68.04%AUD 0.142020-02-12

Emyria Financials at a Glance

Market Cap

A$37.10MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$3.95M

Net Income (TTM)

-A$6.18M

EPS (TTM)

-A$0.01

P/E Ratio

-5.61

Dividend

A$0.00

Beta (Volatility)

-0.06 (Low)

Price

A$0.05

Volume

9,688

Open

A$0.05

Previous Close

A$0.05

Daily Range

A$0.05 - A$0.05

52-Week Range

A$0.04 - A$0.08

Estimated Earnings Date

Sep 1, 2026

EMD News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Emyria

Emyria Limited is a biotechnology firm focused on developing innovative therapies for medical conditions that currently lack effective treatments. The company specializes in cannabinoid-derived pharmaceuticals and is also exploring new MDMA-based drugs to address various health issues.

Products and Services
  • Development of cannabinoid-derived pharmaceuticals
  • Research on MDMA-based therapies for mental health
  • Pipeline products targeting psychological distress and irritable bowel syndrome
Growth Outlook
  • Recent revenue growth of 95% quarter-over-quarter
  • Strong cash position with over AUD 10 million in cash
  • Expansion of clinical trials expected to enhance product pipeline
Financial Highlights
  • Quarterly revenue of AUD 1.44 million, a significant increase
  • Current ratio of 10.76 indicates strong liquidity
  • Net income loss reduced by 9% compared to the previous quarter
Emyria Limited is positioned in a promising sector, focusing on unmet medical needs. The recent revenue growth and strong cash reserves provide a solid foundation for future development. The company's innovative approach to therapy development, particularly in cannabinoid and MDMA-based treatments, aligns with growing market demand for alternative healthcare solutions. With ongoing clinical trials and a robust pipeline, Emyria Limited presents an intriguing opportunity for investors interested in the biotechnology sector.
AI Generated • Jul 30, 2026

Industry

Pharmaceuticals

CEO

Michael Winlo, MD, MBA

Website

emyria.com

Headquarters

Leederville, WA 6007, AU

EMD Financials

Key Financial Metrics (TTM)

Gross Margin

-56.70%

Operating Margin

-186.26%

Net Income Margin

-209.09%

Return on Equity

-52.26%

Return on Capital

-44.69%

Return on Assets

-33.31%

Earnings Yield

-17.83%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$37.10MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

806.56M

Volume

9.69K

Avg. Volume

1.18M

Financials (TTM)

Gross Profit

-A$1.41M

Operating Income

-A$6.80M

EBITDA

-A$4.39M

Operating Cash Flow

-A$4.53M

Capital Expenditure

-A$218.52K

Free Cash Flow

-A$4.75M

Cash & ST Invst.

A$10.50M

Total Debt

A$1.06M

Emyria Performance Analysis

Emyria annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-06-30AUD 1,822,400N/A
20232023-06-30AUD 1,592,466-12.6%
20242024-06-30AUD 2,202,71738.3%
20252025-06-30AUD 1,309,227-40.6%
Emyria sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-302.2%
Q22024-12-31-40.9%
Q42025-06-3011.9%
Q22025-12-3195.4%
Emyria annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-06-30AUD -0.03N/A
20232023-06-30AUD -0.02-35.2%
20242024-06-30AUD -0.0380.2%
20252025-06-30AUD -0.01-78.1%
Emyria sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-3094.8%
Q22024-12-31-35.3%
Q42025-06-30-100.0%
Q22025-12-3123.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

A$1.44M

+32.1%

Gross Profit

-A$1.33M

+16.6%

Gross Margin

-92.22%

N/A

Market Cap

A$37.10MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$6.18M

N/A

Employees

6

N/A

Net Income

-A$2.37M

+78.0%

EBITDA

-A$2.29M

+82.5%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

A$10.50M

+434.1%

Total Debt

A$1.06M

-64.3%

Accounts Receivable

A$249.55K

+364.1%

Inventory

A$0.00

N/A

Long Term Debt

A$1.00M

+34.1%

Short Term Debt

A$55.30K

-97.5%

Return on Assets

-33.31%

N/A

Return on Invested Capital

-32.07%

N/A

Free Cash Flow

-A$2.09M

+53.7%

Operating Cash Flow

-A$2.04M

+54.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MAP.AXMicroba Life Sciences Limited
A$0.05+0.00%
DOC.AXDoctor Care Anywhere Group PLC
A$0.11+0.00%
NXS.AXNext Science Limited
A$0.15+0.00%
EYE.AXNova Eye Medical Limited
A$0.15-3.23%

Trending Stocks

Symbol / CompanyPricePrice Chg
ONDSOndas
$8.91-0.09%
SMCISuper Micro Computer
$39.16+0.04%
SPCXSpace Exploration Technologies
$141.29-0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.64+0.07%

Questions About EMD

What is the current price of Emyria?

Emyria is trading at A$0.05 per share.

What is the 52-week range for Emyria?

Over the past 52 weeks, Emyria has traded between A$0.04 and A$0.08.

How much debt does Emyria have?

As of the most recent reporting period, Emyria reported total debt of A$613.50K.

How much cash does Emyria have on hand?

Emyria reported A$3.57M in cash and cash equivalents in its most recent financial results.

What is Emyria’s dividend yield?

Emyria does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.